|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. 4. Where are the gaps between what the public sector needs and what industry is already doing? Gap Analysis and Discussion 1:30 RECONVENE ELEMENT 2: A LEARNING CASE—THE CHILDREN'S VACCINE INITIATIVE 5. What have we learned? (NOTE: While particular topics are indicated for some individuals, all are highly knowledgeable about this activity and can speak to a range of relevant points.) Panel Presentation and Discussion—Attempts to Modify the Structure of Incentives for Industry to Produce ''Social Products": The Illuminating Case of the Children's Vaccine Initiative William Hausdorff (Wyeth-Lederle) Pamela Johnson (United Nations) Amie Batson (Vaccine Supply and Quality Unit, WHO Global Programme for Vaccines and Immunization) William Muraskin (Department of History, Queens College) Jack Melling (Salk Institute, Swiftwater) Roy Widdus (WHO/Children's Vaccine Initiative) Patents: Protection and Problems Charles Caruso (Merck and Company, Inc.) ELEMENT 3: OTHER MODELS AND MECHANISMS Special Disease-Focused Initiatives: Malaria Vaccine Development Board Phillip Russell (Johns Hopkins School of Hygiene and Public Health) International AIDS Vaccine Initiative (IAVI) Seth Berkley (Rockefeller Foundation) Legislative Mechanisms Orphan Drug Act Anne Marie Finley (Committee on Government Reform and Oversight, Subcommittee on Human Resources, U.S. House of Representatives)
|
||||||||||||||||
